Earnings Releases·Nov 4, 2026, 7:03 AM ET

BioCryst Pharmaceuticals — Third Quarter 2026 Earnings Summary

Total net revenue reached $180.3 million (up 13% year-over-year), with GAAP operating profit rising to $53.3 million and non-GAAP net income increasing to $71.1 million compared to the prior year period.
Full-year 2026 total revenue guidance was raised to $715–$730 million (from $690–$715 million), while non-GAAP operating expense guidance was lowered to $415–$425 million, driven by higher licensing revenues and cost savings from the Birmingham site closure.
ORLADEYO net revenue totaled $174.8 million, supported by the August launch of oral pellets for pediatric patients, October FDA approval for the 150 mg formulation in patients aged 12+, and a new sole-source partnership with CareMed.
Strategic pipeline updates include the discontinuation of the STAR-0310 atopic dermatitis program to focus on rare diseases, with BCX17725 expected to report early clinical data by end of 2026 and Navenibart pivotal results anticipated in Q3 2027.
The company reported positive cash flow with $376.4 million in cash and investments, though the balance sheet includes $395.6 million in secured term loans and $421.7 million in royalty financing obligations.